October 15, 2024
1 min watch
Save
VIDEO: Data on neuroprotective agents for geographic atrophy discussed at ASRS
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Barbara Blodi, MD, discusses early data on neuroprotective agents for the treatment of geographic atrophy.
In a phase 1b study presented during a dry AMD symposium at the ASRS meeting, the fatty acid synthase inhibitor ONL1204 (ONL Therapeutics) showed safety and tolerability.
In addition, Blodi discusses the phase 2/3 trial of AVD-104 (Aviceda Therapeutics) for geographic atrophy.
References:
- Borkar D, et al. Fas inhibition with ONL1204 for the treatment of geographic atrophy: First-time results from a phase 1b study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
- Singh R, et al. Results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy: Glyco-immunologic modulation of macrophage activity. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Blodi reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.